China License Out

Announced Date: 2025-09-03 (September 3, 2024) Asset Name: Four siRNA programs  Licensor: Shanghai Argo Biopharmaceutical (China) … [China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA ProgramsRead more

Announced Date: 2025-08-29 (August 29, 2025) Asset Name: KY-0301 Licensor: Novatim (Novatim Immune Therapeutics, China) Licensee … [China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301Read more

Announced Date: 2025-08-26 (August 26, 2025) Asset Name: FXS6837 （Other code: XH-S003） Licensor: Fosun Pharma and … [China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837Read more

Announced Date: 2025-08-19 (August 19, 2025) Asset Name: RC28-E Intravitreal Injection Licensor: RemeGen (RemeGen Co., Ltd., … [China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF/FGF Fusion Protein RC28-ERead more

Announced Date: 2025-08-11 (August 11, 2025) Asset Name: XH-S004 Licensor: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. … [China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004Read more

Announced Date: 2025-07-30 (JULY 30, 2025) Asset Name: SYH2086 Licensor: CSPC Pharmaceutical Group Limited (HKEX Stock … [China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086Read more

Announced Date: 2025-07-28 (JULY 28, 2025) Asset Name: HRS-9821 and other 11 preclinical medicines Licensor: Hengrui … [China BD 2025] Hengrui and GSK  achieved a 12.5 billion USD license on PDE3/4 inhibitor HRS-9821 and 11 other assetsRead more

Announced Date: 2025-05-19 (May 19, 2025), 2025-07-24 updated Asset Name: SSGJ-707 Licensor: 3SBio, Inc (01530.HK) (Headquarter Shanghai … [China BD Deal] 3SBio and Pfizer Completes a 6 billion License on PD-1/VEGF BsAbs SSGJ-707Read more